周剂量伊立替康联合雷替曲塞在晚期大肠癌二线治疗中的效果及安全性分析.docVIP

周剂量伊立替康联合雷替曲塞在晚期大肠癌二线治疗中的效果及安全性分析 邬宇飞 展军 陶涛 江苏省张家港澳洋医院三兴分院肿瘤内科 X 关注成功！ 加关注后您将方便地在 我的关注中得到本文献的被引频次变化的通知！ 新浪微博 腾讯微博 人人网 开心网 豆瓣网 网易微博 摘????要： 目的 探讨周剂量伊立替康联合雷替曲塞二线治疗晚期大肠癌的疗效及安全性。方法 选取2014年3月至2016年9月间张家港澳洋医院三兴分院收治的66例晚期结直肠腺癌患者, 均经过奥沙利铂与氟尿嘧啶 (5-FU) (FOLFOX方案) 一线治疗。按照入院先后顺利分为观察组和对照组, 每组33例, 观察组患者采用周剂量伊立替康联合雷替曲塞作为二线治疗方案, 对照组患者采用伊立替康、5-FU和亚叶酸钙 (FOLFIRI方案) 治疗。评估并比较两组患者临床疗效和不良反应。结果 观察组患者疾病控制率为84.8%, 高于对照组患者的69.7%, 差异有统计学意义 (P0.05) 。观察组患者恶心呕吐和粒细胞减少ⅢⅣ度发生率分别为21.2%和15.2%, 低于对照组的36.4%和33.3%, 差异均有统计学意义 (均P0.05) 。结论 FOLFOX一线化疗方案治疗失败的晚期大肠癌患者, 采用周剂量伊立替康联合雷替曲塞作为二线治疗方案, 临床效果能够显著提高, 不良反应较低, 具有较好的安全性。 关键词： 伊立替康; 雷替曲塞; 晚期大肠肿瘤; 临床疗效; 安全性; 作者简介：邬宇飞, 男, 主治医师, 主要从事肿瘤内科专业。 收稿日期：2017-02-17 Efficacy and safety of weekly dosing of irinotecan combined with raltitrexed as second-line therapy for advanced colorectal cancer WU Yu-fei ZHAN JUN TAO Tao Department of Oncology, Zhangjiagang Aoyang Hospital Sanxing Branch; Abstract： Objective To discuss the efficacy and safety of weekly dosing of irinotecan combined with raltitrexed as second-line therapy for advanced colorectal cancer. Methods Sixty-six patients with advanced colorectal cancer diagnosed and treated at Zhangjiagang Aoyang Hospital Sanxing Branch from March 2014 to September 2016 were selected. All the patients received oxaliplatin plus fluorouracil ( 5-FU) ( FOLFOX) as first-line chemotherapy regimen. According to the admission sequence, patients were randomly divided into an observation group and a control group with 33 patients in each group. The observation group was given weekly dosing of irinotecan combined with raltitrexed as the second-line therapy and the control group was treated with FOLFIRI second-line regimen. The clinical efficacy and adverse reactions were evaluated. Results The disease control rate was 84. 8% for the observation group which was higher than 69. 7%of the control group ( P 0. 05) . The incidence of nausea or vomiting and grade Ⅲ ~ Ⅳ neutropenia 21. 2% and 15. 2%, respectively for the observation